Date: Jun 6, 2017 10:00 AM - 02:30 PM
Registration closes on Jun 06, 2017 10:00 AM
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict. The existence of relationships does not necessarily imply bias or lessen the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers. The relevant commercial financial relationships or affiliations must have occured over the past 12 months.
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity. Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
Requirements for CE Credit
Registration closes on Jun 06, 2017
at 10:00 AM
- Identify monitoring strategies and compliance to ensure appropriate use of opioid prescriptions
- Outline strategies to prevent opioid abuse by counseling patients on proper storage and disposal practice
- Describe validated risk screening tools for aberrant drug taking behaviors as well as their utility and limitations
- Select appropriate toxicology screening and interpret results to ensure safe use of opioids
Chris Herndon, Pharm.D., BCPS, CPE, FASHP
Brief Bio : Associate Professor, Department of Pharmacy Practice, SIUE and Clinical Assistant Professor, Department of Community and Family Medicine, St. Louis University School of Medicine. Clinical interest: Pain Management.
Disclosure : Conflict of Interest Disclosures: The presenter has completed and submitted the SIUE School of Pharmacy Continuing Pharmacy Education Form for Disclosure of Potential Conflicts of Interest and none were reported.
- Explain the importance of maximizing the use of non-pharmacological interventions to treat chronic pain
- Describe the CDC Opioid Prescribing Guideline’s recommendation regarding dose limits
- Specify reasons why naloxone co-prescribing might be indicated
- List three other steps that can be taken to increase safety of opioid prescribing
Bob Twillman, Ph.D., FAPM
Brief Bio : Bob Twillman, Ph.D., is the Executive Director for the Academy of Integrative Pain Management. Dr. Twillman oversees federal and state pain policy developments and advocates for those supporting an integrative approach to managing pain. He also serves as Chair of the Prescription Monitoring Program Advisory Committee for the Kansas Board of Pharmacy. Dr. Twillman received his Ph.D. in Clinical Psychology at the University of California in Los Angeles, and maintains a volunteer faculty appointment as Clinical Associate Professor of Psychiatry and Behavioral Sciences at the University Of Kansas School Of Medicine in Kansas City, KS.
Disclosure : The presenter has completed and submitted the SIUE School of Pharmacy Continuing Pharmacy Education Form for Disclosure of Potential Conflicts of Interest and none were reported.